Saturday 17 October 2026
Export OKYO’s income statement to Excel — free account
OKYO Pharma Limited Sponsored ADR
OKYO Healthcare Biotechnology
Insiders bought in the last twelve months.
1.41
0.02
−1.40%
Follow OKYO
| Mar '26 | Sep '25 | Mar '25 | Sep '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
2.43 | 0.58 | 0.40 | 0.28 |
+7 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 4.00% | 0.00% | 0.06% | |
Debt/Equity |
0.00 | (0.05) | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(3.39) | 0.00 | (0.46) | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | — | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(5.94) | (1.53) | (1.81) | (0.24) | |
Working Capital |
12.33 | (3.42) | (5.55) | (7.23) | |
Capital Expenditures |
(0.01) | — | 0.00 | — | |
Net Current Asset Value |
12.33 | (3.42) | (5.55) | (7.23) | |
| Other line items | |||||
Quick Ratio |
2.43 | 0.58 | 0.40 | 0.28 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | — | |
Average Receivables |
0.54 | 0.79 | 1.62 | 1.72 | |
Average Payables |
7.85 | 5.95 | 5.24 | 5.46 | |
Average Assets |
11.26 | 4.92 | 2.77 | 3.57 | |
Average Common Equity |
3.23 | (2.73) | (2.96) | (2.14) | |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates